Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus

Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus

Author Weffort, Roberta Frota Villas-Boas Autor UNIFESP Google Scholar
Ramos-Dias, João Carlos Autor UNIFESP Google Scholar
Chipoch, Conrado Autor UNIFESP Google Scholar
Lengyel, Ana Maria Judith Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract In insulin-dependent diabetes mellitus (IDDM), inappropriate growth hormone (GH) responses to several stimuli, including GH-releasing hormone (GHRH), have been described, A decreased hypothalamic somatostatinergic tone is one of the most likely explanations for these findings. His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GH-releasing peptide-6 [GHRP-6]) is a synthetic hexapeptide that stimulates GH release in vitro and in vivo, The mechanism of action of GHRP-6 is unknown, but it probably does not inhibit hypothalamic somatostatin secretion. Also, GHRH and GHRP-6 apparently activate different intracellular pathways to release GH, The aim of this study was to evaluate whether there is a differential effect of IDDM on GHRP-6- and GHRH-induced GH secretion, Six patients with IDDM and seven control subjects were studied. Each subject received GHRP-6 (1 mu g/kg intravenously [IV]), GHRH (100 mu g IV), and GHRP-6 + GHRH on 3 separate days. GH peak values (mean +/- SE in micrograms per liter) were similar in controls and diabetics after GHRH (22.5 +/- 7.8 v 24.0 +/- 9.7) and after GHRP-6 (20.5 +/- 5.3 v 24.4 +/- 6.3). The association of GHRP-6 and GHRH induced a significantly higher GH release than administration of the isolated peptides in both groups. The synergistic GH response to combined administration of GHRP-6 and GHRH was not different in controls (70.5 +/- 20.0) and diabetics (119.0 +/- 22.2), In summary, the effectiveness of GHRP-6 in IDDM could reinforce the evidence that this peptide probably does not release GH through a decrease in hypothalamic somatostatin secretion, Moreover, our data suggest that both GHRH and GHRP-6 releasing mechanisms are unaltered in IDDM. Copyright (C) 1997 by W.B. Saunders Company.
Language English
Date 1997-06-01
Published in Metabolism-clinical And Experimental. Philadelphia: W B Saunders Co, v. 46, n. 6, p. 706-710, 1997.
ISSN 0026-0495 (Sherpa/Romeo, impact factor)
Publisher W B Saunders Co
Extent 706-710
Access rights Closed access
Type Article
Web of Science ID WOS:A1997XC87300018

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account